Compare Enveric Biosciences Inc (ENVB) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Consumer Staples Select Sector SPDR Fund trades at $83.45 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 1985.3× Enveric Biosciences Inc's market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| ENVB | XLP | |
|---|---|---|
Market Cap | $6.80M | $13.50B |
Volume | 64,867 | 14,599,953 |
Sector | Health | — |
52-Week High | $10.80 | $90.00 |
52-Week Low | $1.27 | $75.61 |
Typical Hold Time | 14 Days | 72 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
XLP trades at $81.70, showing slight weakness with a 0.09% decline amid bearish technical signals. The ETF maintains strong analyst support with a 100% buy rating from 2 analysts, though technical indicators show moving averages and overall signals are bearish. Recent news highlights XLP's defensive characteristics and competitive expense ratio advantage over peers.
The consumer staples ETF offers defensive exposure during market volatility, supported by positive sector performance in 2026. Key risks include interest rate sensitivity and potential consumer spending slowdowns. Analyst consensus remains bullish despite technical headwinds, positioning XLP as a core defensive holding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
